Scholarlink

Introduction <p>In disorders of gut–brain interaction including functional dyspepsia and irritable bowel syndrome, clinical focus has shifted from pathophysiological criteria to symptoms.</p> Methods <p>A&#xa0;single-arm, low-intervention clinical trial into the effectiveness and tolerability of Menthacarin, a&#xa0;peppermint oil/caraway oil combination, was performed. A total of 126 patients with abdominal pain/cramps or a&#xa0;sensation of being bloated without organic cause received 1&#xa0;capsule Menthacarin twice a&#xa0;day for 8&#xa0;weeks. Assessments included abdominal symptoms, stool parameters, and quality of life.</p> Results <p>During treatment, all assessed abdominal symptoms showed significant (<i>p</i> &lt; 0.001), clinically meaningful improvements, with standardized effect sizes of 0.83–1.05 for change from baseline. The number of days/week with symptom impact or incomplete spontaneous bowel movements almost halved, while days/week with normal stool consistency increased (all <i>p</i> &lt; 0.001). Health-related quality of life significantly improved (<i>p</i> &lt; 0.001) and Menthacarin was well tolerated.</p> Conclusion <p>The study demonstrates patient-relevant improvement in gastrointestinal symptoms during treatment with Menthacarin while underlining its favorable tolerability profile.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment of disorders of gut–brain interaction with peppermint oil and caraway oil combination Menthacarin

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月17日

查看全文
  • Ioannis Linas,
  • Stephan R. Vavricka,
  • Jost Langhorst,
  • Daniel Pohl,
  • Berenike Stracke,
  • Andrea Zimmermann,
  • Petra Funk,
  • Ingolf Schiefke,
  • Ahmed Madisch

摘要

Introduction

In disorders of gut–brain interaction including functional dyspepsia and irritable bowel syndrome, clinical focus has shifted from pathophysiological criteria to symptoms.

Methods

A single-arm, low-intervention clinical trial into the effectiveness and tolerability of Menthacarin, a peppermint oil/caraway oil combination, was performed. A total of 126 patients with abdominal pain/cramps or a sensation of being bloated without organic cause received 1 capsule Menthacarin twice a day for 8 weeks. Assessments included abdominal symptoms, stool parameters, and quality of life.

Results

During treatment, all assessed abdominal symptoms showed significant (p < 0.001), clinically meaningful improvements, with standardized effect sizes of 0.83–1.05 for change from baseline. The number of days/week with symptom impact or incomplete spontaneous bowel movements almost halved, while days/week with normal stool consistency increased (all p < 0.001). Health-related quality of life significantly improved (p < 0.001) and Menthacarin was well tolerated.

Conclusion

The study demonstrates patient-relevant improvement in gastrointestinal symptoms during treatment with Menthacarin while underlining its favorable tolerability profile.